| Literature DB >> 28503510 |
Seo Eun Yeon1, Sun Jung Kim2, Ju Hee Kim3, Hae-Yun Chung4, Se Hee Na5, Song Mi Lee1.
Abstract
A 30-year-old female patient, 18 weeks gestational age, with no prior medical history was admitted to hospital complaining severe right upper quadrant pain. The patient was admitted to intensive care unit (ICU) after emergency surgery to treat intraperitoneal hemorrhage caused by rupture of liver hematoma. Despite the absence of high blood pressure, the patient was diagnosed with hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome on the basis of abnormal levels of blood aspartate aminotransferase/alanine aminotransferase, lactate dehydrogenase, total bilirubin, direct bilirubin, C-reactive protein (CRP) and platelet along with liver damage and proteinuria. While in ICU, the patient was given total parenteral nutrition (TPN) and enteral nutrition (EN) for -20 days because oral feeding was impractical. In the early stage, TPN supply was not sufficient to meet the elevated nutritional demand induced by disease and surgery. Nevertheless, continuous care of nutrition support team enabled satisfactory EN and, subsequently, oral feeding which led to improvement in patient outcome.Entities:
Keywords: Enteral nutrition; HELLP syndrome; Nutrition support; Parenteral nutrition
Year: 2017 PMID: 28503510 PMCID: PMC5426206 DOI: 10.7762/cnr.2017.6.2.136
Source DB: PubMed Journal: Clin Nutr Res ISSN: 2287-3732
Clinical characteristics of the patient on admission
| General characteristics | Value | |
|---|---|---|
| Age, yr | 30 | |
| Sex | Female | |
| Anthropometric indexes | ||
| Height, cm | 159 | |
| Body weight, kg | 55 | |
| Body weight before pregnancy, kg | 51 | |
| Vital signs | ||
| Body temperature, ℃ | 36 | |
| Pulse rate, bpm | 111 | |
| Systolic/diastolic blood pressure, mmHg | 72/42 | |
Figure 1Progression of nutritional support and clinical aspects of the patient.
HOD, hospital onset of day; NST consult, nutrition support team consult; NSVD, normal spontaneous vaginal delivery; TPN, total parenteral nutrition.
Figure 2The amount of energy delivery during hospital stays.
HOD, hospital onset of day.
Figure 3The amount of protein delivery during hospital stays.
HOD, hospital onset of day.
Results of biochemical test of the patient
| Test | Normal range | HOD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 7 | 10 | 13 | 16 | 19 | 22 | 24 | 29 | Outpatient clinic | ||
| CRP, mg/L | 0.1–6.0 | 39.0 | 197.7 | 266.1 | 253.6 | 218.8 | 185.5 | 79.0 | 42.9 | 40.6 | 7.7 | - |
| Albumin, g/dL | 3.4–5.3 | 2.8 | 2.9 | 2.7 | 2.8 | 2.9 | 3.2 | 3.2 | 3.5 | 3.3 | 3.9 | 4.2 |
| Glucose, mg/dL | 80–118 | 115 | 84 | 119 | 105 | 122 | 208 | 142 | 136 | 110 | 101 | 64 |
| Calcium, mg/dL | 8.6–10.0 | 7.1 | 8.1 | 8.2 | 7.4 | 8.2 | 8.9 | 9.4 | 9.6 | 9.2 | 9.7 | 9.6 |
| Inorganic P, mg/dL | 2.8–4.5 | 2.7 | 2.8 | 2.5 | 2.2 | 2.7 | 2.4 | 3.6 | 3.7 | 5.0 | 4.1 | 4.2 |
| Alk. Phos, IU/L | 35–83 | 103 | 103 | 82 | 92 | 199 | 264 | 292 | 292 | 266 | 272 | 95 |
| AST (GOT), IU/L | 14–30 | 3,179 | 565 | 66 | 48 | 64 | 50 | 63 | 35 | 41 | 40 | 28 |
| ALT (GPT), IU/L | 6–33 | 1,881 | 500 | 112 | 38 | 37 | 40 | 66 | 53 | 43 | 56 | 30 |
| T. Bilirubin, mg/dL | 0.2–1.2 | 5.2 | 4.3 | 2.4 | 3.0 | 2.3 | 2.1 | 1.6 | 1.2 | 1.3 | 0.9 | 0.7 |
| D. Bilirubin, mg/dL | 0.0–0.2 | 2.1 | 2.9 | 1.5 | 1.9 | 1.4 | 1.3 | 1.0 | 0.8 | 0.7 | 0.5 | - |
| Amylase, U/L | 25–97 | 211 | 53 | 86 | 108 | 68 | 73 | 117 | 127 | 123 | 88 | - |
| Lipase, U/L | 19–59 | 24 | 44 | 95 | 115 | 86 | 95 | 205 | 189 | 138 | 90 | - |
| BUN, mg/dL | 7.0–22.0 | 16.1 | 9.7 | 15.3 | 14.2 | 8.8 | 9.9 | 14.5 | 14.7 | 14.7 | 11.7 | 8.3 |
| Creatinine, mg/dL | 0.65–1.10 | 0.52 | 0.48 | 0.41 | 0.27 | 0.18 | < 0.20 | 0.20 | 0.24 | 0.41 | 0.42 | 0.60 |
| Cholesterol, mg/dL | 139–230 | 65 | 80 | 76 | 94 | 169 | 212 | 230 | 225 | 227 | 265 | 202 |
| Lymphocyte (#), 103/µL | 1.50–4.00 | 0.74 | 0.63 | 0.73 | 0.64 | 0.72 | 0.44 | 0.65 | 0.66 | 0.72 | 1.13 | 1.89 |
| PLT count, 103/µL | 150–400 | 69 | 85 | 149 | 219 | 448 | 566 | 627 | 484 | 360 | 290 | 304 |
| LDH, IU/L | 140–280 | 908 | - | - | - | - | - | - | - | - | - | - |
HOD, hospital onset of day; CRP, C-reactive protein; Alk. Phos, alkaline phosphatase; AST, aspartate aminotransferase; GOT, glutamic oxaloacetic transaminase; ALT, alanine aminotransferase; GPT, glutamic pyruvic transaminase; T. Bilirubin, total bilirubin; D. Bilirubin, direct bilirubin; BUN, blood urea nitrogen; PLT count, platelet count; LDH, lactate dehydrogenase.
Figure 4Changes in the cholesterol, albumin, and serum CRP concentration of the patient.
CRP, C-reactive protein.
Amounts of electrolytes and minerals in the used PN and recommended PN
| Nutrients | Requirement* | Used PN | Recommended PN | |
|---|---|---|---|---|
| Combiflex lipid (1 L) | SmofKabiven (1 L) | |||
| Electrolytes | Na, mEq | 55 (1–2 mEq/kg) | 28.0 | 40.6 |
| K, mEq | 55 (1–2 mEq/kg) | 24.0 | 30.5 | |
| Mg, mEq | 8–20 | 4.0 | 10.1 | |
| Ca, mEq | 10–15 | 3.6 | 5.1 | |
| P, mmol | 20–40 | 12.0 | 12.8 | |
| Minerals | Zn, mg | 2.5–5.0 | - | 2.6 |
| Cu, mg | 0.3–0.5 | - | - | |
| Se, µg | 20–60 | - | - | |
| Mn, mg | 0.06–0.10 | - | - | |
| Cr, µg | 10–15 | - | - | |
The information for each nutritional supplement are follow as: Combiflex lipid 1,000 inj (central), JW Pharmaceutical, Seoul, Korea; SmofKabiven inj (central), Fresenius Kabi AB, Uppsala, Sweden.
PN, parenteral nutrition; Na, sodium; K, potassium; Mg, magnesium; Ca, calcium; P, phosphorus; Zn, zinc; Cu, copper; Se, selenium; Mn, manganese; Cr, chromium.
*This values are referring by Mirtallo et al. [17].
Amounts of vitamins in Tamipool inj
| Vitamins | Requirement* | Tamipool inj |
|---|---|---|
| Vitamin A, mg RE | 990 | 990 |
| Vitamin D, µg | 5 | 5 |
| Vitamin E, IU | 10 | 10 |
| Vitamin K, µg | 150 | - |
| Thiamin, mg | 6.00 | 3.81 |
| Riboflavin, mg | 3.6 | 3.6 |
| Pyridoxine, mg | 6.00 | 4.86 |
| Cyanocobalamin, µg | 5 | 5 |
| Vitamin C, mg | 200 | 100 |
| Pantothenate, mg | 15 | 15 |
| Biotin, µg | 60 | 60 |
| Folate, µg | 600 | 400 |
| Niacin, mg | 40 | 40 |
The information for Tamipool inj is follow as: Tamipool inj, Celltrion Pharm Inc., Cheongju, Korea.
*This values are referring by Mirtallo et al. [17].